EMBO Molecular Medicine (Feb 2019)

Inhibition of Stat3‐mediated astrogliosis ameliorates pathology in an Alzheimer's disease model

  • Nicole Reichenbach,
  • Andrea Delekate,
  • Monika Plescher,
  • Franziska Schmitt,
  • Sybille Krauss,
  • Nelli Blank,
  • Annett Halle,
  • Gabor C Petzold

DOI
https://doi.org/10.15252/emmm.201809665
Journal volume & issue
Vol. 11, no. 2
pp. n/a – n/a

Abstract

Read online

Abstract Reactive astrogliosis is a hallmark of Alzheimer's disease (AD), but its role for disease initiation and progression has remained incompletely understood. We here show that the transcription factor Stat3 (signal transducer and activator of transcription 3), a canonical inducer of astrogliosis, is activated in an AD mouse model and human AD. Therefore, using a conditional knockout approach, we deleted Stat3 specifically in astrocytes in the APP/PS1 model of AD. We found that Stat3‐deficient APP/PS1 mice show decreased β‐amyloid levels and plaque burden. Plaque‐close microglia displayed a more complex morphology, internalized more β‐amyloid, and upregulated amyloid clearance pathways in Stat3‐deficient mice. Moreover, astrocyte‐specific Stat3‐deficient APP/PS1 mice showed decreased pro‐inflammatory cytokine activation and lower dystrophic neurite burden, and were largely protected from cerebral network imbalance. Finally, Stat3 deletion in astrocytes also strongly ameliorated spatial learning and memory decline in APP/PS1 mice. Importantly, these protective effects on network dysfunction and cognition were recapitulated in APP/PS1 mice systemically treated with a preclinical Stat3 inhibitor drug. In summary, our data implicate Stat3‐mediated astrogliosis as an important therapeutic target in AD.

Keywords